Article

New CPT code released for AMD treatment

A new Category III CPT code was released by the American Medical Association Current Procedural Terminology (CPT) Editorial Panel.

Freemont, CA-A new Category III CPT code was released by the American Medical Association Current Procedural Terminology (CPT) Editorial Panel. The code for Neovista Inc.'s radiation therapy for the treatment of wet age-related macular generation (AMD) (0190T) will become effective July 1 and will be used with the code for performing a basic posterior vitrectomy (67036).

"We at NeoVista believe that our unique radiation therapy will eventually be shown to offer a less-time-consuming and less-costly alternative for physicians who treat patients with wet AMD," said John Hendrick, president and chief executive officer of NeoVista. "Obtaining a Category III CPT code is a vital step towards our end-goal of seeing our therapy through to market launch, where it will be of help to millions of people suffering from wet AMD."

The code will eventually allow physicians to identify the novel epiretinal radiation treatment for wet AMD on insurance claims.

The American Academy of Ophthalmology and American Society of Therapeutic and Radiation Oncology supported Neovista through the code development.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.